Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 14, 2019 09:00 ET | Source: H. Lundbeck A/S

Lundbeck and Otsuka report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder

The efficacy of brexpiprazole for the acute treatment of manic episodes, with or without mixed features, in subjects with bipolar I disorder was investigated in two three-week, double-blind,...
February 05, 2019 01:52 ET | Source: H. Lundbeck A/S

Annual Report 2018 for H.Lundbeck A/S

Annual Report 2018 for H.Lundbeck A/S Attachment ANNUALREPORT2018 ...
February 05, 2019 01:40 ET | Source: H. Lundbeck A/S

Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018

Financial report for the period 1 January to 31 December 2018 Lundbeck realized 8% growth in revenue (local currencies) and 48% growth in EPS in 2018 HIGHLIGHTS Revenue reached...
January 22, 2019 00:32 ET | Source: H. Lundbeck A/S

Dr. Johan Luthman appointed EVP and Head of Research & Development in Lundbeck

Valby, Denmark, 22 January 2019 - H. Lundbeck A/S (Lundbeck) today announced that Dr. Johan Luthman has been appointed Executive Vice President and Head of Research & Development in Lundbeck....
January 22, 2019 00:32 ET | Source: H. Lundbeck A/S

Dr. Johan Luthman udnævnt koncerndirektør for forskning og udvikling hos Lundbeck

Valby, Danmark, 22 januar 2019 - H. Lundbeck A/S (Lundbeck) annoncerede i dag, at Dr. Johan Luthman er blevet udnævnt som Executive Vice President og koncerndirektør for forskning og udvikling hos...
December 04, 2018 03:38 ET | Source: H. Lundbeck A/S

Lundbeck announces retirement of Anders Gersel Pedersen, EVP and Head of Research and Development

Valby, Denmark, 4 December 2018 - H. Lundbeck A/S (Lundbeck) today announced that Anders Gersel Pedersen, Executive Vice President and Head of Research and Development (R&D), will retire after 19...
December 04, 2018 03:38 ET | Source: H. Lundbeck A/S

Anders Gersel Pedersen, koncerndirektør for forskning og udvikling hos Lundbeck, går på pension

Valby, Danmark, 4. december 2018 - H. Lundbeck A/S (Lundbeck) annoncerede i dag, at Anders Gersel Pedersen, koncerndirektør for forskning og udvikling, går på pension efter 19 år i firmaet. Anders...
November 30, 2018 03:17 ET | Source: H. Lundbeck A/S

Lundbeck and Otsuka report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD)

Valby, Nov. 30, 2018 (GLOBE NEWSWIRE) -- The combination treatment arm of brexpiprazole and sertraline demonstrated improvement in symptoms of PTSD versus placebo (p<0.01) on the primary...
November 30, 2018 03:17 ET | Source: H. Lundbeck A/S

Lundbeck og Otsuka rapporterer positive fase II-data for kombinationsbehandling med brexpiprazol og sertralin til behandling af post-traumatisk stress syndrom (PTSD)

Valby, Nov. 30, 2018 (GLOBE NEWSWIRE) -- Kombinationsbehandlingsarmen med brexpiprazol og sertralin udviste forbedring af symptomer i PTSD sammenlignet med placebo (p<0.01) på det primære...
November 20, 2018 05:51 ET | Source: H. Lundbeck A/S

Kapitalforhøjelse i Lundbeck med 6.574 aktier (0,0033 % af udestående aktier) som følge af warrant-program for medarbejdere

Valby, Nov. 20, 2018 (GLOBE NEWSWIRE) -- - H. Lundbeck A/S (Lundbeck) har i dag offentliggjort beslutningen om at udvide aktiekapitalen med DKK 32.870 som følge af udnyttelsen af...